Biosystems engineering of prokaryotes with tumor-killing capacities
Date
2016Source Title
Current Pharmaceutical Design
Print ISSN
1381-6128
Electronic ISSN
1873-4286
Publisher
Bentham Science Publishers Ltd.
Volume
22
Issue
11
Pages
1521 - 1528
Language
English
Type
ArticleItem Usage Stats
220
views
views
323
downloads
downloads
Abstract
Certain bacteria selectively attack tumor tissues and trigger tumor shrinkage by producing toxins and modulating the local immune system, but their clinical utility is limited because of the dangers posed by systemic infection. Genetic engineering can be used to minimize the risks associated with tumor-targeting pathogens, as well as to increase their efficiency in killing tumor cells. Advances in genetic circuit design have led to the development of bacterial strains with enhanced tumor-targeting capacities and the ability to secrete therapeutics, cytotoxic proteins and prodrug-cleaving enzymes, which allows their safe and effective use for cancer treatment. The present review details the recent advances in the design and application of these modified bacterial strains.
Keywords
BifidobacteriumCancer therapy
Clostridium
Live vaccines
Prodrug cleavage
Salmonella
Synthetic biology
Antineoplastic agent
Cytotoxic factor
Drug carrier
Flucytosine
Fluorouracil
Ganciclovir
Live vaccine
Probiotic agent
Tretazicar
Unclassified drug
Vnp 20009
Antibiotic therapy
Antineoplastic activity
Article
Bacterial membrane
Bacterial strain
Bifidobacterium
Cancer diagnosis
Cancer recurrence
Cancer therapy
CD8+ T lymphocyte
Cell infiltration
Clostridium
Colony forming unit
Drug activation
Drug delivery system
Escherichia
Gene transfer
Genetic engineering
Immune response
Immunogenicity
Metastasis
Natural killer T cell
Nonhuman
Oxygen concentration
Phase 2 clinical trial (topic)
Priority journal
Prokaryote
Salmonella
Target cell
Tumor microenvironment
Type III secretion system
Animal
Bacterium
Biological therapy
Cytology
Genetics
Human
Metabolism
Microbiology
Neoplasms
Pathophysiology
Prokaryotic cell
Animals
Bacteria
Biological therapy
Humans
Neoplasms
Prokaryotic cells
Permalink
http://hdl.handle.net/11693/36631Published Version (Please cite this version)
http://dx.doi.org/10.2174/1381612822666151210123752Collections
Related items
Showing items related by title, author, creator and subject.
-
Early outcomes after transoral CO2 laser resection of laryngeal and hypopharyngeal squamous cell carcinoma: One centre's experience
Leong, S. C.; Kathan, C.; Mortimore, S. (Cambridge University Press, 2010)Objectives: To review early oncological outcomes following transoral CO2 laser resection of laryngeal and hypopharyngeal squamous cell carcinoma. Design: Retrospective review of hospital electronic database. Setting: Large ... -
A bifunctional photosensitizer for enhanced fractional photodynamic therapy: singlet oxygen generation in the presence and absence of light
Turan, I. S.; Yildiz, D.; Turksoy, A.; Gunaydin, G.; Akkaya, E. U. (Wiley-VCH Verlag, 2016)The photosensitized generation of singlet oxygen within tumor tissues during photodynamic therapy (PDT) is self-limiting, as the already low oxygen concentrations within tumors is further diminished during the process. In ... -
Adjuvant autologous melanoma vaccine for macroscopic stage III disease: survival, biomarkers, and improved response to CTLA-4 blockade
Lotem, M.; Merims, S.; Frank, S.; Hamburger, T.; Nissan, A.; Kadouri, L.; Cohen, J.; Straussman, R.; Eisenberg, G.; Frankenburg, S.; Carmon, E.; Alaiyan, B.; Shneibaum, S.; Ayyildiz, Z. O.; Isbilen, M.; Senses, K. M.; Ron, I.; Steinberg, H.; Smith, Y.; Shiloni, E.; Gure, A. O.; Peretz, T. (Hindawi Limited, 2016)Background. There is not yet an agreed adjuvant treatment for melanoma patients with American Joint Committee on Cancer stages III B and C. We report administration of an autologous melanoma vaccine to prevent disease ...